{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:48:01Z","timestamp":1773798481351,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T00:00:00Z","timestamp":1473638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hemodialysis International"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Introduction:<\/jats:bold> Oral phosphate binders are the main stay of treatment of hyperphosphatemia. Adherence rates to ferric citrate, a recently approved phosphate binder, are unknown.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We conducted a post\u2010hoc analysis to evaluate whether adherence rates were different for ferric citrate vs. active control in 412 subjects with end stage kidney disease (ESKD) who were randomized to ferric citrate vs. active control (sevelamer carbonate and\/or calcium acetate). Adherence was defined as percent of actual number of pills taken to total number of pills prescribed.<\/jats:p><jats:p><jats:bold>Findings:<\/jats:bold> There were no significant differences in baseline characteristics including gender, race\/ethnicity, and age between the ferric citrate and active control groups. Baseline phosphorus, calcium, and parathyroid hormone levels were similar. Mean (SD) adherence was 81.4% (17.4) and 81.7% (15.9) in the ferric citrate and active control groups, respectively (P\u2009=\u20090.88). Adherence remained similar between both groups after adjusting for gender, race\/ethnicity, age, cardiovascular disease (CVD), and diabetic nephropathy (mean [95% CI]: 81.4% [78.2, 84.6] and 81.5% [77.7, 85.2] for ferric citrate and active control, respectively). Gender, race\/ethnicity, age, and diagnosis of diabetic nephropathy did not influence adherence to the prescribed phosphate binder. Subjects with CVD had lower adherence rates to phosphate binder; this was significant only in the active control group.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> Adherence rates to the phosphate binder, ferric citrate, were similar to adherence rates to active control. Similar adherence rates to ferric citrate are notable since tolerance to active control was an entry criteria and the study was open label. Gender, race\/ethnicity, nor age influenced adherence.<\/jats:p>","DOI":"10.1111\/hdi.12487","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T07:27:08Z","timestamp":1473665228000},"page":"243-249","source":"Crossref","is-referenced-by-count":5,"title":["Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis"],"prefix":"10.1111","volume":"21","author":[{"given":"Diana","family":"Jalal","sequence":"first","affiliation":[{"name":"University of Colorado Aurora, Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"McFadden","sequence":"additional","affiliation":[{"name":"University of Utah Salt Lake Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie P.","family":"Dwyer","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kausik","family":"Umanath","sequence":"additional","affiliation":[{"name":"Henry Ford Hospital Detroit Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwin","family":"Aguilar","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Center New Orleans Louisiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoram","family":"Yagil","sequence":"additional","affiliation":[{"name":"Ben\u2010Gurion University of the Negev, Beer Sheba and Barzilai University Medical Center Ashkelon Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Greco","sequence":"additional","affiliation":[{"name":"Baystate Medical Center Springfield Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Sika","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia B.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Greene","sequence":"additional","affiliation":[{"name":"University of Utah Salt Lake Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simin","family":"Goral","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,9,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.04.006"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80446-X"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008020141"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.308"},{"issue":"4","key":"e_1_2_6_6_1","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis."},{"key":"e_1_2_6_7_1","first-page":"5","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"KDIGO.","year":"2012","journal-title":"Kidney Int Suppl."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.12315"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-9-2"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-153"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2013.11.004"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00290109"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh125"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.02.340"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70221-0"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00590.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014020212"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117383"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.11.041"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000341922"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014020212"},{"key":"e_1_2_6_22_1","doi-asserted-by":"crossref","unstructured":"UmanathK JalalDI GrecoBA et al. Ferric citrate reduces intravenous iron and erythropoiesis\u2010stimulating agent use in ESRD.2015;26:2578\u20132587.","DOI":"10.1681\/ASN.2014080842"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv006"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.11.041"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.907791"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144119"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2015.03.001"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(99)80026-5"},{"key":"e_1_2_6_30_1","first-page":"685","article-title":"How should we measure medication adherence in clinical trials and practice?","volume":"3","author":"Lee JK","year":"2007","journal-title":"Ther Clin Risk Manag."},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-014-0062-3"}],"container-title":["Hemodialysis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhdi.12487","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhdi.12487","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hdi.12487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T15:26:47Z","timestamp":1696260407000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hdi.12487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,12]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1111\/hdi.12487"],"URL":"https:\/\/doi.org\/10.1111\/hdi.12487","archive":["Portico"],"relation":{},"ISSN":["1492-7535","1542-4758"],"issn-type":[{"value":"1492-7535","type":"print"},{"value":"1542-4758","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,12]]}}}